Primary- and secondary-prevention trials involving subjects with or at risk for coronary artery disease have previously demonstrated a beneficial effect of conventional-dose statin therapy.
OTC availability would result in an expansion of statin use. Patients could benefit from low-dose statins, despite not having a health plan. A 2004 update of the NCEP guidelines, [9] however ...